Steris

Medical Disinfectant Wipes Global Market Report 2022 - by Type, Material, Distribution, Application and Region

Retrieved on: 
Saturday, January 21, 2023
Benchmark, Kaiser, Centers for Disease Control and Prevention, Clair, Clorox, Coronavirus, Hydrogen peroxide, Health, Supermarket, Hospital, Sale, 3M, Nursing, Reckitt, Growth, Bacteria, Decontamination, Kaiser Family Foundation, Organization, Acquisition, Create, Kimberly-Clark, Virus, Distribution, Steris, Sewage treatment, Risk management, Marketing, Video game, Tissue paper, Health care

The "Medical Disinfectant Wipes Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Disinfectant Wipes Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • This report provides strategists, marketers and senior management with the critical information they need to assess the global medical disinfectant wipes market.
  • The most commonly used medical disinfectant wipes include alcohol disinfectant wipes and alcohol-free disinfectant wipes.
  • The main types of medical disinfectant wipes are surface disinfectant wipes, germicidal disposable wipes, hydrogen peroxide disinfectant wipes, and others.

STERIS Announces Financial Results for Fiscal 2023 Third Quarter

Retrieved on: 
Wednesday, February 8, 2023
NYSE, EPS, STE, Customer, Health care, Environment, Growth, Steris, AST, Dental, Video game

As reported earnings per share of $1.24; adjusted EPS of $2.02

Key Points: 
  • As reported earnings per share of $1.24; adjusted EPS of $2.02
    DUBLIN, IRELAND, Feb. 08, 2023 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2023 third quarter ended December 31, 2022.
  • Constant currency organic revenue (see Non-GAAP Financial Measures) increased 7% for the third quarter of fiscal 2023 as compared to the third quarter of fiscal 2022.
  • Adjusted net income (see Non-GAAP Financial Measures) for the third quarter of fiscal 2023 was $202.3 million or $2.02 per diluted share, compared with the previous year’s third quarter of $213.3 million or $2.12 per diluted share.
  • Operating income was $20.3 million in the third quarter of fiscal 2023 compared with $23.1 million in the prior year’s third quarter.

STERIS to Host a Conference Call for Fiscal 2023 Third Quarter Financial Results on February 9, 2023

Retrieved on: 
Wednesday, January 25, 2023
NYSE, STE, Steris, Mobile phone

DUBLIN, IRELAND, Jan. 25, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2023 third quarter financial results at 10:00 a.m.

Key Points: 
  • DUBLIN, IRELAND, Jan. 25, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2023 third quarter financial results at 10:00 a.m.
  • ET on February 9, 2023.
  • The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.
  • A press release detailing third quarter financial results will be issued after the U.S. market closes on February 8, 2023.

Global Hospital Furniture Market Report 2022: A $20 Billion Market by 2028 - Size, Segments, Outlook, and Revenue Forecasts by Product Type, Manufacturing Material, Application, End User, Region - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 17, 2023
General Health, Manufacturing, Other Manufacturing, Hospitals, Health, Transport, Hospital, Medical tourism, Sprint, COVID-19, Steris, Lifting, Chronic kidney disease, Degenerative disease, Stretcher, Conditional sentence, Operating table, Invacare, Alzheimer's disease, Growth, Patient, Stryker Corporation, Prevalence, Diabetes, Getinge, Cancer, Knoll, Stroke, Examination table, Chronic lung disease, Chronic condition, E-commerce, Video game, Health insurance, Health promotion

The "Global Hospital Furniture Market Size, Segments, Outlook, and Revenue Forecast 2022-2028 by Product Type, Manufacturing Material, Application, End User, Region" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Hospital Furniture Market Size, Segments, Outlook, and Revenue Forecast 2022-2028 by Product Type, Manufacturing Material, Application, End User, Region" report has been added to ResearchAndMarkets.com's offering.
  • According to this analysis, the Global Hospital Furniture Market was valued at ~US$ 7 billion in 2017.
  • The demand for better hospital infrastructure due to rising medical tourism has also boosted the Hospital Furniture Market.
  • High costs attributable to hospital furniture, lack of design and creation, and patient-centered care issues pose challenges to the growth of the Hospital Furniture Market.

The healthcare analytical testing services market is projected to reach USD 11.1 billion by 2027 from USD 6.5 billion in 2022, at a CAGR of 11.4%

Retrieved on: 
Thursday, December 22, 2022
INC, USD, Charles River Laboratories, Pulse, Cros, Intertek, Cinven, Immunogenicity, Drug development, Growth, Sartorius AG, Safety, ICON plc, Steris, LabCorp, Environmental monitoring, SGS, Pressure, Therapy, Parexel, Merck Group, Wuxi, Eurofins Scientific, Fine chemical, Vaccine, Medical device

View original content:https://www.prnewswire.com/news-releases/the-healthcare-analytical-testi...

Key Points: 
  • The healthcare analytical testing services market is projected to reach USD 11.1 billion by 2027 from USD 6.5 billion in 2022, at a CAGR of 11.4%.
  • • Service Development/Innovation: Detailed insights on the upcoming trend, and service launches in the global healthcare analytical testing services market.
  • • Market Diversification: Exhaustive information about new services, growing geographies, and recent developments in the global healthcare analytical testing services market.
  • • Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and services of leading players in the global healthcare analytical testing services market.

STERIS Announces Financial Results for Fiscal 2023 Second Quarter

Retrieved on: 
Wednesday, November 9, 2022
Director, GLOBE, Private Securities Litigation Reform Act, TCJA, Name, Forward-looking statement, STE, Congress, Health care, NYSE, Marketing, Cantel Medical Corporation, Tax Cuts and Jobs Act of 2017, Disclosure, Risk, Literature, Accounting, Health, EPA, Environment, Sale, Board, COVID-19, AST, Legislation, Mission statement, Annual report, Tax, Pressure, Compliance, Time, Company, Steris, Terminology, GAAP, Dental, Growth, Industry, Acquisition, Insurance, FDA, Income, Cryptocurrency, Video game, Health insurance, Bank, Brexit, Customer, EU

DUBLIN, IRELAND, Nov. 09, 2022 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2023 second quarter ended September 30, 2022. Revenue as reported for the quarter was flat at $1.2 billion compared with $1.2 billion in the second quarter of fiscal 2022. Constant currency organic revenue (see Non-GAAP Financial Measures) increased 7% for the second quarter of fiscal 2023 as compared to the second quarter of fiscal 2022.  

Key Points: 
  • Constant currency organic revenue (see Non-GAAP Financial Measures) increased 7% for the second quarter of fiscal 2023 as compared to the second quarter of fiscal 2022.
  • Adjusted net income (see Non-GAAP Financial Measures) for the second quarter of fiscal 2023 was $199.6 million or $1.99 per diluted share, compared with the previous years second quarter of $200.3 million or $1.99 per diluted share.
  • Operating income was $48.6 million in the second quarter of fiscal 2023 compared with $57.5 million in the prior years second quarter.
  • Operating income was $28.1 million in the second quarter of fiscal 2023 compared with $32.4 million in the prior years second quarter.

Centerline Biomedical announces Gulam Khan as Chief Executive Officer

Retrieved on: 
Tuesday, October 4, 2022
Physician, Technology, Health, CEO, Center line, Multimedia, FDA, View, IOPS, Endoscopy, Leadership, Patient, Steris, Nursing, Surgeon, Board, Company, Senior, Management, Mentorship

CLEVELAND, Oct. 4, 2022 /PRNewswire/ -- Centerline Biomedical, Inc. ("Centerline"), which recently commercialized its Intra-Operative Positioning Systems IOPS, has appointed Gulam Khan, Chief Executive Officer.

Key Points: 
  • CLEVELAND, Oct. 4, 2022 /PRNewswire/ -- Centerline Biomedical, Inc. ("Centerline"), which recently commercialized its Intra-Operative Positioning Systems IOPS, has appointed Gulam Khan, Chief Executive Officer.
  • Having lead organizations that focused on new product development, Mr. Khan is passionate about collaborating with physicians, nurses and technicians to improve patient care through product innovation.
  • "We're thrilled to have Gulam join us at this important stage of development for Centerline Biomedical."
  • said Gulam Khan, CEO of Centerline Biomedical.

Ranfac Announces Successful Validation of Secondary Ethelyn Oxide Sterilization Source

Retrieved on: 
Wednesday, August 10, 2022
Quality assurance, View, Multimedia, Steris, ISO, Sterilization, Partnership, COO, EO, Risk management, Medical device

AVON, Mass., Aug. 10, 2022 /PRNewswire/ -- Ranfac Corporation has announced the completion of a successful validation of Steris Corporation as an additional source for Ethelyn Oxide (EO) sterilization services. According to Barry Zimble, Chief Operating Officer at Ranfac, "Having multiple sources of sterilization will add a level of control and an increased sense of reliability." The company claims this was an essential investment during a time of unprecedented supply chain interruptions while also providing adequate capacity to meet emerging demand for sterile packaged goods.  

Key Points: 
  • AVON, Mass., Aug. 10, 2022 /PRNewswire/ -- Ranfac Corporation has announced the completion of a successful validation of Steris Corporation as an additional source for Ethelyn Oxide (EO) sterilization services.
  • According to Barry Zimble, Chief Operating Officer at Ranfac, "Having multiple sources of sterilization will add a level of control and an increased sense of reliability."
  • -Barry Zimble, COO
    "What we don't want are bottlenecks, points of slowed movement, in our supply chain," stated Michael Faradie, Ranfac Director of Manufacturing.
  • According to Eric Kreuz, Ranfac Vice President of Quality Assurance and Regulatory Assurance, this validation will positively affect risk management at the company.

STERIS Announces Financial Results for Fiscal 2023 First Quarter

Retrieved on: 
Tuesday, August 2, 2022
Cantel Medical Corporation, Name, EPA, Acquisition, Sale, Congress, Tax, Time, GLOBE, STE, Literature, Industry, Legislation, Health, Disclosure, Forward-looking statement, NYSE, Government, Compliance, Private Securities Litigation Reform Act, Growth, Personal protective equipment, Marketing, Income, Board, COVID-19, Steris, GAAP, Director, Mission statement, FDA, Company, TCJA, Tax Cuts and Jobs Act of 2017, Pressure, Annual report, Terminology, Accounting, EPS, AST, Risk, Dental, List of life sciences, Pharmaceutical industry, Video game, Bank, EU, Health care, Brexit, Customer

First quarter revenue increases 19% as reported; 6% constant currency organic

Key Points: 
  • First quarter revenue increases 19% as reported; 6% constant currency organic
    As reported EPS of $1.10; adjusted EPS of $1.90
    DUBLIN, IRELAND, Aug. 02, 2022 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (STERIS or the Company) today announced financial results for its fiscal 2023 first quarter ended June 30, 2022.
  • Constant currency organic revenue (see Non-GAAP Financial Measures) increased 6% for the first quarter of fiscal 2023 as compared to the first quarter of fiscal 2022.
  • Operating income was $55.3 million in the first quarter of fiscal 2023 compared with $49.1 million in the prior years first quarter.
  • Net cash provided by operations for the first quarter of fiscal 2023 was $231.7 million, compared with $97.4 million in the first quarter of fiscal 2022.

Varex Names Kathleen L. Bardwell to Board of Directors

Retrieved on: 
Tuesday, August 2, 2022
Technology, Radiology, Health, Security, CPAS, Executive Committee, Certified Public Accountant, Corporation, Quality, AICPA, First Financial Bank (Ohio), American Institute, Ethanolamine, Internal audit, Ethics, History, National Association of Corporate Directors, Accounting, Housing, Communities and Local Government Committee, Compliance, First, American Institute of Certified Public Accountants, National Association, Board, VREX, MainSource Bank, CRMA, Ohio Society of New York, Steris, Business administration, Audit committee, Senior, Board of directors, Security, Youngstown State University, NACD, Certification, Youngstown, Ohio, Regulatory affairs, National Executive Committee of the Labour Party, Audit

Varex Imaging Corporation (Varex) (Nasdaq: VREX) today announced that Kathleen L. Bardwell has been appointed to the companys Board of Directors, effective July 29, 2022.

Key Points: 
  • Varex Imaging Corporation (Varex) (Nasdaq: VREX) today announced that Kathleen L. Bardwell has been appointed to the companys Board of Directors, effective July 29, 2022.
  • In connection with this appointment, the Varex Board of Directors increased its size from seven to eight directors.
  • I am very pleased to have Kathie join the Varex Board of Directors.
  • Kathies experience will be a valuable asset to the company, and we welcome her to our Board of Directors, said Ruediger Naumann-Etienne, Chairman of the Board of Directors of Varex Imaging Corporation.